公开(公告)号：US20230310405A1

公开(公告)日：2023-10-05

申请号：US18021654

申请日：2021-08-19

Applicant: BIOGEN MA INC.

Inventor： Shibeshih Belachew ,  Ellen Cahir-McFarland ,  Zhaohui Shao ,  Hui-Hsin Tsai ,  Ru Wei

IPC: A61K31/445 ,  A61K45/06 ,  A61P3/06

CPC classification number: A61K31/445 ,  A61K45/06 ,  A61P3/06

Abstract: Disclosed is a method of lowering elevated cholesterol plasma levels in a subject. Also disclosed is a method of treating hypercholesterolemia in a subject. The methods comprise administering to the subject in the absence of a cholesterol lowering drug an effective amount of Compound 1 or pharmaceutically acceptable salt thereof.

公开(公告)号：US10017506B2

公开(公告)日：2018-07-10

申请号：US15296601

申请日：2016-10-18

Applicant: BIOGEN MA INC.

Inventor： Kevin M. Guckian ,  Gnanasambandam Kumaravel ,  Bin Ma ,  Sha Mi ,  Hairuo Peng ,  Zhaohui Shao ,  Lihong Sun ,  Arthur G. Taveras ,  Deping Wang ,  Zhili Xin ,  Lei Zhang

IPC: A61K31/015 ,  A61K31/4375 ,  A61K31/44 ,  C07D451/02 ,  C07D217/22 ,  A61K31/472 ,  A61K45/06 ,  A61K31/4725 ,  C07D401/06

CPC classification number: C07D451/02 ,  A61K31/136 ,  A61K31/196 ,  A61K31/439 ,  A61K31/445 ,  A61K31/46 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/5375 ,  A61K31/55 ,  A61K45/06 ,  C07B2200/07 ,  C07C217/22 ,  C07C229/46 ,  C07C229/48 ,  C07C255/59 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/42 ,  C07D209/52 ,  C07D211/34 ,  C07D211/62 ,  C07D217/22 ,  C07D221/22 ,  C07D223/06 ,  C07D295/096 ,  C07D401/06 ,  C07D471/08 ,  Y02A50/401

Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.

公开(公告)号：US09550798B2

公开(公告)日：2017-01-24

申请号：US14417293

申请日：2013-07-26

Applicant: BIOGEN MA INC.

Inventor： Kevin Guckian ,  Gnanasambandam Kumaravel ,  Bin Ma ,  Sha Mi ,  Hairuo Peng ,  Zhaohui Shao ,  Lihong Sun ,  Arthur Taveras ,  Zhili Xin ,  Lei Zhang

IPC: C07C229/48 ,  C07D223/06 ,  C07D221/22 ,  C07D209/52 ,  C07D211/62 ,  C07D295/096 ,  A61K31/5375 ,  A61K31/439 ,  A61K31/46 ,  A61K31/445 ,  A61K31/196 ,  A61K31/136 ,  C07F7/08 ,  A61K45/06 ,  A61K31/195 ,  A61K31/41 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/5513 ,  C07D215/38 ,  C07D217/22 ,  C07D401/04 ,  C07D471/08 ,  C07C217/58 ,  C07C229/46 ,  C07C233/61 ,  C07C235/66 ,  A61K31/397 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/495 ,  A61K31/496 ,  A61K31/506 ,  A61K31/551 ,  A61K31/695 ,  C07C211/38 ,  C07D205/04 ,  C07D213/74 ,  C07D215/20 ,  C07D401/06

CPC classification number: C07F7/081 ,  A61K31/195 ,  A61K31/196 ,  A61K31/397 ,  A61K31/403 ,  A61K31/41 ,  A61K31/439 ,  A61K31/451 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K45/06 ,  C07C211/38 ,  C07C217/58 ,  C07C229/46 ,  C07C229/50 ,  C07C233/60 ,  C07C233/61 ,  C07C235/66 ,  C07C2102/10 ,  C07C2102/42 ,  C07C2102/44 ,  C07C2102/50 ,  C07C2103/62 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2602/42 ,  C07C2602/44 ,  C07C2602/46 ,  C07C2602/50 ,  C07C2603/62 ,  C07C2603/74 ,  C07D205/04 ,  C07D209/52 ,  C07D211/14 ,  C07D213/74 ,  C07D215/12 ,  C07D215/20 ,  C07D215/38 ,  C07D217/22 ,  C07D239/42 ,  C07D241/20 ,  C07D295/096 ,  C07D401/04 ,  C07D401/06 ,  C07D451/02 ,  C07D451/14 ,  C07D471/08 ,  C07D491/107 ,  C07F7/0805 ,  A61K2300/00

Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

Abstract translation: 式（I）化合物可以调节一种或多种SIP受体的活性和/或自分泌素（ATX）的活性。

公开(公告)号：US20150315273A1

公开(公告)日：2015-11-05

申请号：US14677521

申请日：2015-04-02

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber ,  Steven D. Miklasz ,  Christilyn Graff

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。